Produced | Sohu Health
Author | Zhou Yichuan
Edit | Yuan Yue
On August 25, Fuxing International announced its 2021 interim results, in which the overall revenue of the health sector increased by 18.7% year-on-year. The phase II clinical trials of the mRNA new crown vaccine BNT162b2 in China (excluding Hong Kong, Macao and Taiwan) are also progressing in an orderly manner.
The report pointed out that in the first half of 2021, the overall revenue of Fosun International Group’s health sector was RMB 19.28 billion, a year-on-year increase of 18.7%; it benefited from the strong year-on-year growth in the profit attributable to shareholders of the parent company of Fosun Pharma and the related secondary market equity in the health sector. Driven by the increase in the fair value of investments, the profit attributable to shareholders of the parent company in this segment reached RMB 1.21 billion during the reporting period, a year-on-year increase of 233.6%.
Fubitai (mRNA new crown vaccine, namely BNT162b2) is included in the government vaccination program in Hong Kong and Macau, China. During the reporting period, revenue of more than RMB 500 million was realized. In addition, Fosun Pharma intends to supply 15 million doses of mRNA COVID-19 vaccine to Taiwan, China, and the vaccine will be donated to the disease control agency in Taiwan for local vaccination. At the same time, the phase II clinical trials of the mRNA new crown vaccine BNT162b2 in China (excluding Hong Kong, Macao and Taiwan) are also progressing in an orderly manner.
In March this year, Gland Pharma announced that it would produce and supply up to 252 million doses of Russian “Sputnik V” new crown vaccine; in June, Fosun Pharma’s first domestic CAR-T cell therapy product, Fosun Kate’s Akirensai injection Liquid was approved for listing; In July, Fu Rui Medical Technology obtained the relicensing right of Revance Therapeutics, Inc.’s long-acting neuromodulator RT002 in Greater China.
In terms of social responsibility, Fosun, while developing at a rapid pace, is taking advantage of its own industry to actively give back to the society through charity activities such as supporting the fight against the epidemic, rural doctors, education and culture, and entrepreneurship support.
In April 2021, the epidemic prevention and control situation in India and other countries and regions deteriorated. The Fosun Foundation and friendly enterprises donated medical supplies such as oxygen concentrators, ventilators, masks, etc., which were urgently needed to India. So far, the Fosun Foundation has donated more than 10 million materials to various provinces and cities in China, as well as overseas countries such as India, Cambodia, Indonesia, and Nepal in 2021. At the same time, since the outbreak of the new crown epidemic in 2020, the total number of anti-epidemic supplies that Fosun has assisted globally has exceeded 147 million.
Guo Guangchang, Chairman of Fosun International, stated that in the future, Fosun will lead corporate governance and development with “higher growth, co-enterprise, and more responsibilities”, assume more social responsibilities, continue to create value, return to society, and help promote high-quality development and promotion Common prosperity.
Return to Sohu to see more
Editor in charge:
Disclaimer: The opinions of this article only represent the author himself. Sohu is an information publishing platform. Sohu only provides information storage space services.
.